Compare Kyndryl Holdings Inc (KD) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Zimmer Biomet Holdings Inc — how do they compare? Kyndryl Holdings Inc trades at $11.75 (market cap $2.59B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 6.5× Kyndryl Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kyndryl Holdings Inc for 36 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| KD | ZBH | |
|---|---|---|
Market Cap | $2.59B | $16.95B |
Volume | 5,354,348 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $29.76 | $103.98 |
52-Week Low | $10.59 | $79.58 |
Typical Hold Time | 36 Days | 89 Days |
Enterprise Value | $5.41B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl Holdings (KD) trades at $11.88, up 3.76% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 EPS beat but missed Q4 2025 and Q1 2026 expectations. Fundamentals show improving profitability with 2025 net income of $252M (1.67% margin) and strong cash flow generation of $236M. Recent news highlights AI-focused initiatives including new innovation labs and strategic acquisitions.
Outlook remains cautious with analyst consensus at Hold (71.42%) and $14.67 price target offering 23% upside. Key risks include inconsistent earnings performance, competitive pressures in IT services, and high debt levels at 30.67% debt-to-asset ratio. The stock presents potential for recovery if AI investments translate to sustained revenue growth and margin expansion.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
